Capecitabine Clinical Trials

5 recruiting

Capecitabine Trials at a Glance

6 actively recruiting trials for capecitabine are listed on ClinicalTrialsFinder across 6 cities. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Beijing, Beijing, and Chengdu. Lead sponsors running capecitabine studies include Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Affiliated Hospital of Qinghai University, and Eye & ENT Hospital of Fudan University.

Browse capecitabine trials by phase

Treatments under study

About Capecitabine Clinical Trials

Looking for clinical trials for Capecitabine? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Capecitabine trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Capecitabine clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Advanced CancerPancreatic AdenocarcinomaCapecitabine+5 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences30 enrolled1 locationNCT06405490
Recruiting
Not Applicable

Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome

Breast CancerElectroacupunctureCapecitabine+3 more
Affiliated Hospital of Qinghai University220 enrolled1 locationNCT06602167
Recruiting
Phase 2

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

Colo-rectal CancerCapecitabineCetuximab
West China Hospital150 enrolled1 locationNCT05022030
Recruiting
Phase 2

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

CapecitabineTislelizumabBevacizumab+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences52 enrolled1 locationNCT05970302
Recruiting

A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma

to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally Advanced Hypopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University74 enrolled1 locationNCT05940441
Recruiting
Phase 2

Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

RadiotherapyCapecitabinePD-1 Inhibitor+1 more
Fifth Affiliated Hospital, Sun Yat-Sen University28 enrolled1 locationNCT05290194